A citation-based method for searching scientific literature

Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
Times Cited: 308



Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Hans J Woerle, Uli C Broedl. Diabetes Care 2013
Times Cited: 269




List of shared articles



Times cited

Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis.
Abolfazl Akbari, Mahdi Rafiee, Thozhukat Sathyapalan, Amirhossein Sahebkar. J Diabetes Res 2022
0

Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials.
Alicia Swee Yan Yip, Shariel Leong, Yao Hao Teo, Yao Neng Teo, Nicholas L X Syn, Ray Meng See, Caitlin Fern Wee, Elliot Yeung Chong, Chi-Hang Lee, Mark Y Chan,[...]. Ther Adv Chronic Dis 2022
0

Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently.
Marc Evans, Angharad R Morgan, Stephen C Bain, Sarah Davies, Umesh Dashora, Smeeta Sinha, Samuel Seidu, Dipesh C Patel, Hannah Beba, W David Strain. Diabetes Ther 2022
0

Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
Tobias Täger, Dan Atar, Stefan Agewall, Hugo A Katus, Morten Grundtvig, John G F Cleland, Andrew L Clark, Hanna Fröhlich, Lutz Frankenstein. Heart Fail Rev 2021
10

Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults.
Mohamad Sirri Tarazi, Samir Touhamy, Beverly G Tchang, Alpana P Shukla. Expert Opin Pharmacother 2021
0

Sodium-glucose cotransporter 2 inhibitors for the management of type 2 diabetes.
Maka Siamashvili, Stephen N Davis. Expert Opin Pharmacother 2021
1



Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
Juan José Gorgojo-Martínez, Samuel J P Malkin, Virginia Martín, Nino Hallén, Barnaby Hunt. J Med Econ 2020
9

Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial.
Hirohito Sone, Tatsuroh Kaneko, Kosuke Shiki, Yoshifumi Tachibana, Egon Pfarr, Jisoo Lee, Naoko Tajima. Diabetes Obes Metab 2020
9

Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?
Silvio E Inzucchi, David Fitchett, Dubravka Jurišić-Eržen, Vincent Woo, Stefan Hantel, Christina Janista, Stefan Kaspers, Jyothis T George, Bernard Zinman. Diabetes Obes Metab 2020
41


Differences Between Randomized Clinical Trial Participants and Real-World Empagliflozin Users and the Changes in Their Glycated Hemoglobin Levels.
Nicolai E Munk, Jakob S Knudsen, Anton Pottegård, Daniel R Witte, Reimar W Thomsen. JAMA Netw Open 2020
10


Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease.
Kazuomi Kario, Keith C Ferdinand, James H O'Keefe. Prog Cardiovasc Dis 2020
26

An evaluation of empagliflozin and it's applicability to hypertension as a therapeutic option.
Lakshini Y Herat, Vance B Matthews, Aaron L Magno, Marcio G Kiuchi, Revathy Carnagarin, Markus P Schlaich. Expert Opin Pharmacother 2020
3

Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
Ona Kinduryte Schorling, Douglas Clark, Isabella Zwiener, Stefan Kaspers, Jisoo Lee, Hristo Iliev. Adv Ther 2020
8

Anti-inflammatory effects of sodium-glucose co-transporter 2 inhibitors on atherosclerosis.
Yingxiu Kang, Fenfen Zhan, Minzhi He, Zhenjie Liu, Xiaoxiao Song. Vascul Pharmacol 2020
13


Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials.
Daisuke Yabe, Atsutaka Yasui, Linong Ji, Moon-Kyu Lee, Ronald Ching Wan Ma, Tien-Jyun Chang, Tomoo Okamura, Cordula Zeller, Stefan Kaspers, Jisoo Lee,[...]. J Diabetes Investig 2019
17

Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk.
Yangli Ye, Chenhe Zhao, Jing Liang, Yinqiu Yang, Mingxiang Yu, Xinhua Qu. Front Pharmacol 2019
17

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Tadashi Toyama, Brendon L Neuen, Min Jun, Toshiaki Ohkuma, Bruce Neal, Meg J Jardine, Hiddo L Heerspink, Muh Geot Wong, Toshiharu Ninomiya, Takashi Wada,[...]. Diabetes Obes Metab 2019
107


Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control.
Manash Pratim Baruah, B M Makkar, Vikrant B Ghatnatti, Kaushik Mandal. Indian J Endocrinol Metab 2019
5

The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection.
Charalampos Loutradis, Eirini Papadopoulou, Marietta Theodorakopoulou, Asterios Karagiannis, Pantelis Sarafidis. Future Med Chem 2019
14

Clinical parameters affecting the therapeutic efficacy of empagliflozin in patients with type 2 diabetes.
Yun Kyung Cho, Jiwoo Lee, Yu Mi Kang, Jee Hee Yoo, Joong-Yeol Park, Chang Hee Jung, Woo Je Lee. PLoS One 2019
3

SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects.
Anastasios Tentolouris, Panayotis Vlachakis, Evangelia Tzeravini, Ioanna Eleftheriadou, Nikolaos Tentolouris. Int J Environ Res Public Health 2019
63

Effect of Empagliflozin on Free Fatty Acids and Ketone Bodies in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
Rimei Nishimura, Yuko Tanaka, Kazuki Koiwai, Kosuke Ishida, Afshin Salsali, Stefan Kaspers, Sven Kohler, Søren S Lund. Adv Ther 2019
9

Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure.
Konstantinos Imprialos, Konstantinos Stavropoulos, Vasilios Papademetriou. Heart Fail Clin 2019
0


Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.
Helena W Rodbard, Julio Rosenstock, Luis H Canani, Chaicharn Deerochanawong, Janusz Gumprecht, Søren Østergaard Lindberg, Ildiko Lingvay, Anette Luther Søndergaard, Marianne Bach Treppendahl, Eduard Montanya. Diabetes Care 2019
121

The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data.
Serhat Ozcelik, Mehmet Celik, Aski Vural, Bunyamin Aydin. North Clin Istanb 2019
2

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
David Z I Cherney, Mark E Cooper, Ilkka Tikkanen, Egon Pfarr, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Søren S Lund. Kidney Int 2018
105

No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis.
Xiaoling Cai, Xueying Gao, Wenjia Yang, Yifei Chen, Simin Zhang, Lingli Zhou, Xueyao Han, Linong Ji. J Diabetes Investig 2018
32

The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis.
Xiaoling Cai, Wenjia Yang, Xueying Gao, Yifei Chen, Lingli Zhou, Simin Zhang, Xueyao Han, Linong Ji. Obesity (Silver Spring) 2018
67

Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
John Mondick, Matthew Riggs, Stefan Kaspers, Nima Soleymanlou, Jan Marquard, Valerie Nock. J Clin Pharmacol 2018
6

Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study.
Robert R Henry, Julio Rosenstock, Douglas S Denham, Prakash Prabhakar, Lise Kjems, Michelle A Baron. Diabetes Care 2018
15